DR. REDDY'S LABORATORIES-ADR

RDY represents Dr. Reddy's Laboratories Limited, an Indian pharmaceutical company. It is listed on the New York Stock Exchange as an American Depositary Receipt (ADR). The company develops, manufactures, and markets a wide range of generic medicines, active pharmaceutical ingredients, and over-the-counter products. Its global operations span numerous countries, with a significant presence in the United States, India, Russia, and other emerging markets.

Recent performance of RDY stock can be found in the price chart and performance metrics on this page. These display changes over various time frames, such as daily, weekly, monthly, and year-to-date. For the most accurate and up-to-date information, please refer to the live data provided above, as stock prices fluctuate continuously during market hours.

To evaluate RDY's valuation, investors commonly examine metrics such as the price-to-earnings (P/E) ratio, price-to-sales (P/S), and price-to-book (P/B). Comparing these ratios to industry peers and the company's own historical averages provides context. Additionally, discounted cash flow analysis can estimate intrinsic value. The valuation metrics displayed on this page offer a starting point for further research.

Trading of RDY outside regular U.S. market hours is possible through pre-market and after-hours sessions, though liquidity is typically lower and spreads may be wider. These extended hours are facilitated by electronic communication networks (ECNs). However, not all brokers offer this service, and trading volumes can be thin, which may affect execution prices. Always check with your brokerage for specific availability.

Yes, RDY pays dividends. As an ADR of Dr. Reddy's Laboratories, the dividend distribution reflects the company's policy and financial performance. Dividend payments are typically made in Indian rupees and converted to U.S. dollars for ADR holders. The dividend yield and payment history are available on this page. Investors should consider that dividend amounts can vary based on earnings and company decisions.

Key financial metrics for RDY include revenue growth, net income, earnings per share (EPS), operating margin, and return on equity (ROE). These indicate profitability and efficiency. Additionally, cash flow from operations, debt levels, and research and development spending are crucial for a pharmaceutical company. Comparing these metrics over time and against peers helps assess RDY's financial health and competitive position.